Genetic Testing and Clinical Management Practices for Variants in Non-<i>BRCA1</i>/<i>2</i> Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working GroupSarah M. Nielsen, Jana Soukupová, Iris L. Romero et al.|JCO Precision Oncology|2018Cited by 28
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).Antonino Musolino, Filippo Montemurro, A. Caldara et al.|Journal of Clinical Oncology|2017Cited by 0